Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Below 200-Day Moving Average – Here’s Why

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)’s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.91 and traded as low as $1.53. Aldeyra Therapeutics shares last traded at $1.55, with a volume of 471,861 shares trading hands.

Trending Headlines about Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Schall, Pomerantz, and others, reiterated that investors who bought ALDX between November 3, 2023 and March 16, 2026 may be eligible to participate in the class action before the May 29 deadline. Article Title
• Neutral Sentiment: Bronstein, Gewirtz & Grossman said a class action lawsuit has already been filed against Aldeyra and certain officers, alleging violations of federal securities laws and seeking damages for shareholders. Article Title
• Neutral Sentiment: Investors are also being urged by firms such as SueWallSt and the Schall Law Firm to review alleged shortcomings in Aldeyra’s disclosures, which keeps litigation risk in focus for the stock. Article Title

Wall Street Analysts Forecast Growth

ALDX has been the subject of several recent research reports. Weiss Ratings cut shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. Wall Street Zen lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. HC Wainwright reissued a “neutral” rating and issued a $2.00 price target (down from $10.00) on shares of Aldeyra Therapeutics in a report on Wednesday, March 18th. Finally, BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, March 17th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Stock Performance

The company has a 50-day moving average of $1.84 and a 200-day moving average of $3.91. The firm has a market capitalization of $93.50 million, a price-to-earnings ratio of -3.37 and a beta of 1.16.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.07. As a group, analysts anticipate that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard Douglas bought 70,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Thursday, March 19th. The stock was purchased at an average cost of $1.40 per share, with a total value of $98,000.00. Following the purchase, the director owned 195,000 shares in the company, valued at approximately $273,000. This trade represents a 56.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On Aldeyra Therapeutics

A number of large investors have recently bought and sold shares of ALDX. Krilogy Financial LLC acquired a new position in shares of Aldeyra Therapeutics during the 1st quarter worth about $26,000. Abel Hall LLC acquired a new position in shares of Aldeyra Therapeutics during the 1st quarter worth about $26,000. Chicago Partners Investment Group LLC acquired a new position in shares of Aldeyra Therapeutics during the 1st quarter worth about $33,000. Caption Management LLC boosted its stake in shares of Aldeyra Therapeutics by 110.6% during the 2nd quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after buying an additional 132,358 shares during the last quarter. Finally, Inspirion Wealth Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics in the 4th quarter valued at approximately $52,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.